Prevenar 20

The vaccine is a homogeneous white suspension.
One dose (0.5 mL) contains: Pneumococcal polysaccharide serotype 1^1,2 2.2 μg; Pneumococcal polysaccharide serotype 3^1,2 2.2 μg; Pneumococcal polysaccharide serotype 4^1,2 2.2 μg; Pneumococcal polysaccharide serotype 5^1,2 2.2 μg; Pneumococcal polysaccharide serotype 6A^1,2 2.2 μg; Pneumococcal polysaccharide serotype 6B^1,2 4.4 μg; Pneumococcal polysaccharide serotype 7F^1,2 2.2 μg; Pneumococcal polysaccharide serotype 8^1,2 2.2 μg; Pneumococcal polysaccharide serotype 9V^1,2 2.2 μg; Pneumococcal polysaccharide serotype 10A^1,2 2.2 μg; Pneumococcal polysaccharide serotype 11A^1,2 2.2 μg; Pneumococcal polysaccharide serotype 12F^1,2 2.2 μg; Pneumococcal polysaccharide serotype 14^1,2 2.2 μg; Pneumococcal polysaccharide serotype 15B^1,2 2.2 μg; Pneumococcal polysaccharide serotype 18C^1,2 2.2 μg; Pneumococcal polysaccharide serotype 19A^1,2 2.2 μg; Pneumococcal polysaccharide serotype 19F^1,2 2.2 μg; Pneumococcal polysaccharide serotype 22F^1,2 2.2 μg; Pneumococcal polysaccharide serotype 23F^1,2 2.2 μg; Pneumococcal polysaccharide serotype 33F^1,2 2.2 μg.
¹Conjugated to CRM₁₉₇ carrier protein (approximately 51 μg per dose).
²Adsorbed on aluminium phosphate (0.125 mg aluminium per dose).
Excipients/Inactive Ingredients: Sodium chloride, Succinic acid, Polysorbate 80, Water for injections.
For adjuvant, see as previously mentioned.

Pharmacotherapeutic group: vaccines, pneumococcal vaccines. ATC code: J07AL02.
Pharmacology: Pharmacodynamics: Mechanism of action: Prevenar 20 contains 20 pneumococcal capsular polysaccharides all conjugated to CRM₁₉₇ carrier protein, which modifies the immune response to the polysaccharide from a T-cell independent response to a T-cell dependent response. The T-cell dependent response leads to a higher antibody response, and induces antibodies that enhance opsonisation, phagocytosis and killing of pneumococci to protect against pneumococcal disease, as well as generation of memory B-cells, allowing for an anamnestic (booster) response on re-exposure to the bacterium.
Vaccination with Prevenar 20 induces serum antibody production and immunologic memory against the serotypes contained within the vaccine. In adults, the levels of circulating antibodies, and in paediatric populations the serotype-specific levels, that correlate with protection against pneumococcal disease have not been clearly defined.
Clinical efficacy: No efficacy studies have been performed with Prevenar 20.
Immunogenicity data: Prevenar 20 clinical trials in infants, children, and adolescents: Immunogenicity was assessed by serotype-specific IgG response rates (the proportion of participants meeting the serotype-specific IgG level of ≥0.35 μg/mL or equivalent assay-specific value) and IgG GMCs at 1 month following the primary series and 1 month following the toddler dose. OPA GMTs were also measured 1 month following the primary series and following the toddler dose. The predefined concentration corresponding to 0.35 μg/mL in the WHO enzyme-linked immunosorbent assay (ELISA) (or equivalent assay-specific threshold value) is only applicable at the population level and cannot be used to predict individual or serotype-specific protection against invasive pneumococcal disease (IPD). No correlate of protection exists for pneumonia and acute otitis media (AOM).
Two Phase 3 clinical trials (Study 1011, Study 1012) and one Phase 2 clinical trial (Study 1003) evaluated the immunogenicity of Prevenar 20 in a 3-dose or a 4-dose series in infants. One Phase 3 study (Study 1014) of children 15 months to less than 18 years of age evaluated a single dose of Prevenar 20.
Pneumococcal IgG immune responses following 2 and 3 doses in a 3-dose vaccination series: In Study 1012, 1,204 infants 2 months (≥42 to ≤112 days) of age at the time of consent and born at >36 weeks of gestation were randomised (1:1) and vaccinated with either Prevenar 20 or Prevenar 13. The first dose was given at enrolment, a second dose approximately 2 months later, and the third dose at approximately 11 to 12 months of age.
One month after 2 infant doses, the observed IgG GMCs for 9 of the 13 matched serotypes were non-inferior to those in the Prevenar 13 group, and 4 of the 13 matched serotypes (6A, 6B, 9V, and 23F) did not meet the 2-fold statistical criterion for non-inferiority. The percentages of participants with specified serotype-specific IgG concentrations 1 month after Dose 2 of Prevenar 20 for 4 of the 13 matched serotypes were non-inferior to those of the Prevenar 13 group based on a 10% difference non-inferiority criteria, and 9 of the 13 matched serotypes (1, 3, 4, 5, 6A, 6B, 9V, 18C and 23F) did not meet non-inferiority.
The immune responses to the additional 7 serotypes after Prevenar 20 were non-inferior to the lowest IgG GMC among the 13 serotypes (serotype 6B) in Prevenar 13. For the 7 additional serotypes, the percentages of participants with specified serotype-specific IgG concentrations 1 month after Dose 2 of Prevenar 20 for 5 of the 7 additional serotypes were non-inferior to the serotype with the lowest percentage among the 13 serotypes (serotype 6B) in the Prevenar 13 group and serotypes 10A and 12F did not meet the statistical non-inferiority criterion. The clinical relevance of these findings is unknown. Additionally, the IgG GMCs for the 7 additional serotypes were higher compared with the IgG GMCs from the corresponding serotypes in the Prevenar 13 group after two infant doses. One month after the third (toddler) dose, the observed IgG GMCs of Prevenar 20 were non-inferior to the Prevenar 13 group for 12 of 13 matched serotypes except for serotype 6B and all 7 additional serotypes were non-inferior to the lowest IgG GMC in the Prevenar 13 group. Additionally, the IgG GMCs for the 7 additional serotypes were higher compared with the IgG GMCs from the corresponding serotypes in the Prevenar 13 group after the toddler dose.
Functional responses, as measured by OPA GMTs, for the 13 matched serotypes at 1 month after the second infant dose and 1 month after the toddler dose in the Prevenar 20 group were generally similar to the observed OPA GMTs in the Prevenar 13 group for most serotypes and the observed OPA GMTs were substantially higher for the 7 additional serotypes at both timepoints in the Prevenar 20 group than in the Prevenar 13 group. Increases in IgG and OPA antibody responses after Prevenar 20 following Dose 2 to after Dose 3 were observed for all 20 serotypes including those that missed non inferiority, indicative of immunological memory.
Immune responses following 3 and 4 doses in a 4-dose infant vaccination series: In Study 1011, conducted in the United States and Puerto Rico, 1,991 healthy infants aged 2 months (≥42 to ≤98 days) at the time of consent and born at >36 weeks of gestation, were randomised (1:1) and vaccinated with either Prevenar 20 or Prevenar 13 at approximately 2, 4, 6, and 12 to 15 months of age. Participants also received other paediatric vaccines including a combination vaccine containing diphtheria, tetanus, pertussis (acellular), hepatitis B (rDNA), poliomyelitis (inactivated), and a Haemophilus influenzae type b conjugate vaccine (adsorbed) with all 3 doses, and measles, mumps, rubella combination vaccine, and varicella vaccine at the toddler dose. Rotavirus and influenza vaccines were permitted to be co-administered in the study.
One month after the third infant dose, non-inferiority (NI) for the difference in percentages of participants with specified serotype-specific IgG concentrations (with a 10% NI criterion) was met for 9 of the 13 matched serotypes and missed for 4 serotypes (serotypes 3, 4, 9V, and 23F) (Table 1). Six of the 7 additional serotypes also met the non-inferiority criterion when compared to the lowest result for a vaccine serotype in the Prevenar 13 group (excluding serotype 3); serotype 12F missed the statistical non-inferiority criterion. IgG GMCs 1 month after dose 3 of Prevenar 20 were non inferior (with a 0.5 NI criterion for IgG geometric mean ratio (GMR)) to those in the Prevenar 13 group for all 13 matched serotypes. The NI criterion was also met for the 7 additional serotypes to the lowest IgG GMC (excluding serotype 3) among the vaccine serotypes in the Prevenar 13 group (Table 1).
The antibody levels for all 7 additional serotypes were significantly higher than the corresponding serotype in the Prevenar 13 group (Tables 1 and 2).
One month after the toddler dose, NI for IgG GMCs (with a 0.5 NI criterion for IgG GMR) was met for all 13 matched serotypes. The NI criterion was also met for the 7 additional serotypes to the lowest IgG GMC (excluding serotype 3) among the vaccine serotypes in the Prevenar 13 group (Table 2). Although non-inferiority was not formally tested for this endpoint, the observed differences (Prevenar 20 – Prevenar 13) in percentages of participants with specified serotype-specific IgG concentrations 1 month after Dose 4 were greater than - 10% for all 13 matched serotypes except serotype 3 (-16.4%, CI -21.0%, -11.8%). For the 7 additional serotypes, the observed differences in percentage of participants with specified serotype-specific IgG concentrations 1 month after Dose 4 ranged from -11.5% (serotype 12F) to 1.8% (serotype 15B, 22F, and 33F) (Table 2). (See Tables 1 and 2.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

OPA GMTs for the 13 matched serotypes in the Prevenar 20 group were generally comparable to the OPA GMTs in the Prevenar 13 group 1 month after the third infant dose, and they were slightly lower than in the Prevenar 13 group for most serotypes after the toddler dose. There is variability of the OPA data due to small sample sizes, while interpretation of the clinical relevance of slightly lower OPA GMTs is unknown. The observed OPA GMTs for the 7 additional serotypes were substantially higher in the Prevenar 20 group than in the Prevenar 13 group. Prevenar 20 immune responses also show boosting of IgG concentrations and OPA GMTs after the toddler dose, indicating that a memory response was elicited by the 3 infant doses.
Children and adolescents 15 months to less than 18 years of age (Study 1014): In a multicentre, single-arm trial (Study 1014), participants were enrolled into the study by age group (approximately 200 participants per group) to receive a single-dose Prevenar 20 as described as follows.
Children 15 months to less than 24 months of age previously vaccinated with Prevenar 13: In 15 months to less than 24 months age group, participants had been previously vaccinated with 3 or 4 doses of Prevenar 13. Increases in IgG concentrations from before to 1 month after Prevenar 20 were observed for all 20 vaccine serotypes. The observed IgG geometric mean fold rises (GMFRs) to the 7 additional serotypes ranged from 27.9 to 1847.7.
Children 24 months to less than 5 years of age previously vaccinated with Prevenar 13: In 24 months to less than 5 years age group, participants had been previously vaccinated with 3 or 4 doses of Prevenar 13. Increases in IgG concentrations from before to 1 month after Prevenar 20 were observed for all 20 vaccine serotypes. The observed IgG GMFRs to the 7 additional serotypes ranged from 36.6 to 796.2. For the 7 additional serotypes, 71.2% to 94.6% had ≥4-fold rise in OPA titres.
Children and adolescents 5 years to less than 18 years of age previously unvaccinated or vaccinated with Prevenar 13: In participants 5 years to less than 10 years and 10 years to less than 18 years of age, irrespective of prior vaccination history with Prevenar 13. Prevenar 20 elicited robust IgG and OPA immune responses to the 20 vaccine serotypes after a single dose in participants 5 to less than 18 years of age. OPA GMFRs ranged from 11.5 to 499.0 to the 7 additional serotypes and increases in OPA GMTs were observed for all 20 vaccine serotypes.
Preterm infants: No immunogenicity data is available with Prevenar 20 in preterm infants. Based on experience with Prevenar and Prevenar 13, immune responses are elicited in preterm infants, although they may be lower than in term infants. The safety and tolerability of Prevenar 20 were evaluated in Phase 3 study (Study 1013), which included 111 late preterm infants (infants born at 34 to less than 37 weeks of gestational age) among the total study population. Participants were randomised to receive a 4-dose series of either Prevenar 20 (N=77) or Prevenar 13 (N=34).
Prevenar 20 clinical trials in adults: Three Phase 3 clinical trials, B7471006, B7471007 and B7471008 (Study 1006, Study 1007, and Study 1008), were conducted in the United States and Sweden evaluating the immunogenicity of Prevenar 20 in different adult age groups, and in participants who were either pneumococcal vaccine-naïve, or previously vaccinated with Prevenar 13, PPSV23, or both.
Each study included participants who were healthy or immunocompetent with stable underlying conditions, including chronic cardiovascular disease, chronic pulmonary disease, renal disorders, diabetes mellitus, chronic liver disease, and medical risk conditions and behaviours (e.g., smoking) that are known to increase the risk of serious pneumococcal pneumonia and IPD. In the pivotal study (Study 1007), these risk factors were identified in 34%, 32%, and 26% of participants 60 years of age and over, 50 to 59 years of age, and 18 to 49 years of age, respectively. A stable medical condition was defined as a medical condition not requiring significant change in therapy in the previous 6 weeks (i.e., change to new therapy category due to worsening disease), or any hospitalisation for worsening disease within 12 weeks before receiving the study vaccine.
In each study, immune responses elicited by Prevenar 20 and the control pneumococcal vaccines were measured by an opsonophagocytic activity (OPA) assay. OPA assays measure functional antibodies to Streptococcus pneumoniae.
Comparison of immune responses of Prevenar 20 to Prevenar 13 and PPSV23: In a randomised, active-controlled, double-blind, non-inferiority clinical trial (Pivotal Study 1007) of Prevenar 20 in the United States and Sweden, pneumococcal vaccine-naïve participants 18 years of age and older were enrolled into 1 of 3 cohorts based on their age at enrolment (18 to 49, 50 to 59, and ≥60 years of age), and randomised to receive Prevenar 20 or control. Participants 60 years of age and older were randomised in a 1:1 ratio to receive Prevenar 20 (n=1,507) followed 1 month later with the administration of saline placebo or Prevenar 13 (n=1,490), and with the administration of PPSV23 1 month later. Participants 18 to 49 years of age and 50 to 59 years of age were randomly assigned (3:1 ratio); they received a dose of Prevenar 20 (18 to 49 years of age: n=335; 50 to 59 years of age: n=334) or Prevenar 13 (18 to 49 years of age: n=112; 50 to 59 years of age: n=111).
Serotype-specific OPA GMTs were measured before the first vaccination and 1 month after each vaccination. Non-inferiority of immune responses, OPA GMTs 1 month after vaccination, with Prevenar 20 to a control vaccine for a serotype was declared if the lower bound of the 2-sided 95% confidence interval (CI) for the GMT ratio (Prevenar 20/Prevenar 13; Prevenar 20/PPSV23) for that serotype was greater than 0.5.
In participants 60 years of age and older, the immune responses to all 13 matched serotypes elicited by Prevenar 20 were non-inferior to those elicited by Prevenar 13 for the same serotypes 1 month after vaccination. In general, numerically lower geometric mean titres were observed with Prevenar 20 in the matched serotypes compared to Prevenar 13 (Table 3), however the clinical relevance of these findings is unknown.
The immune responses induced by Prevenar 20 to 6/7 additional serotypes were non-inferior to those induced by PPSV23 to the same serotypes 1 month after vaccination. The response to serotype 8 missed the pre-specified statistical non-inferiority criterion (the lower bound of the 2-sided 95% CI for the GMT ratio is 0.49 instead of >0.50) (Table 3). The clinical relevance of this observation is unknown. Supportive analyses for other serotype 8 endpoints in the Prevenar 20 group showed favourable outcomes. These include a GMFR of 22.1 from before vaccination to 1 month post-vaccination, 77.8% of participants achieved a ≥4-fold rise in OPA titres from before vaccination to 1 month after vaccination, and 92.9% of participants achieved OPA titres ≥LLOQ 1 month after vaccination. (See Table 3.)

Click on icon to see table/diagram/image

Immunogenicity in participants 18 through 59 years of age: In Study 1007, participants 50 through 59 years of age and participants 18 through 49 years of age were randomly assigned (3:1 ratio) to receive 1 vaccination with Prevenar 20 or Prevenar 13. Serotype-specific OPA GMTs were measured before vaccination and 1 month after vaccination. With both vaccines, higher immune responses were observed in younger participants compared with older participants. A non-inferiority analysis of Prevenar 20 in the younger age group versus Prevenar 20 in participants 60 through 64 years of age per serotype was performed to support the indication in adults 18 through 49 years of age and 50 through 59 years of age. Non-inferiority was declared if the lower bound of the 2-sided 95% CI for the GMT ratio (Prevenar 20 in participants 18 through 49 years of age/60 through 64 years of age and in 50 through 59 years of age/60 through 64 years of age) for each of the 20 serotypes was >0.5. Prevenar 20 elicited immune responses to all 20 vaccine serotypes in the two of the younger age groups that were non-inferior to responses in participants 60 through 64 years of age 1 month after vaccination (Table 4).
While not planned as an active control for immunogenicity evaluations in the study, a post hoc descriptive analysis showed generally numerically lower OPA geometric mean titres 1 month after Prevenar 20 for the matched serotypes compared to Prevenar 13 in participants 18 through 59 years of age, however the clinical relevance of these findings is unknown.
As noted previously, individuals with risk factors were included in this study. Across all the age groups studied, in general, a numerically lower immune response was observed in participants with risk factors compared to participants without risk factors. The clinical relevance of this observation is unknown. (See Table 4.)

Click on icon to see table/diagram/image

Immunogenicity of Prevenar 20 in adults previously vaccinated with pneumococcal vaccine: A Phase 3 randomised, open-label clinical trial (Study 1006) described immune responses to Prevenar 20 in participants 65 years of age and older previously vaccinated with PPSV23, with Prevenar 13, or with Prevenar 13 followed by PPSV23. Participants previously vaccinated with Prevenar 13 (Prevenar 13 only or followed by PPSV23) were enrolled at sites in the United States, whereas participants and previously vaccinated with PPSV23 only were also enrolled from Swedish sites (35.5% in that category).
Prevenar 20 elicited immune responses to all 20 vaccine serotypes in participants 65 years of age and older with prior pneumococcal vaccination (Table 5). Immune responses were lower in participants in both groups who received prior PPSV23 vaccinations. (See Table 5.)

Click on icon to see table/diagram/image

Concomitant vaccine administration: Clinical trial in adults to assess Prevenar 20 given with influenza vaccine, adjuvanted (Fluad Quadrivalent [QIV]): In a double-blind, randomised study B7471004 (Study 1004), adults 65 years of age and older were randomised in a 1:1 ratio to receive Prevenar 20 concomitantly administered with an influenza vaccine, adjuvanted (Fluad Quadrivalent [QIV]) (Group 1, N=898) or Prevenar 20 administered 1 month after receiving QIV (Group 2, N=898). Pneumococcal serotype-specific OPA GMTs were evaluated 1 month after Prevenar 20 and influenza vaccine strain hemagglutinin inhibition assay (HAI) GMTs were evaluated 1 month after QIV. The non-inferiority criteria for the comparisons of OPA GMTs (lower limit of the 2- sided 95% CI of the GMT ratio [Group 1/Group 2] >0.5, 2-fold non-inferiority criterion) were met for all 20 pneumococcal serotypes in Prevenar 20. The non-inferiority criteria for the comparisons of HAI GMTs (lower limit of the 2-sided 95% CI for the GMT ratio [Group 1/Group 2] >0.67, 1.5-fold non-inferiority criterion) were also met for all 4 influenza vaccine strains.
Clinical trial in adults to assess Prevenar 20 given with a third (booster) dose of COVID-19 mRNA vaccine (nucleoside modified): In a double-blind, randomised descriptive study B7471026 (Study 1026), adults 65 years of age and older who had received 2 doses of COVID-19 mRNA vaccine (nucleoside modified) at least 6 months earlier, were randomized in a 1:1:1 ratio to receive Prevenar 20 concomitantly administered with a third (booster) dose of COVID-19 mRNA vaccine (nucleoside modified) (N=190), Prevenar 20 administered alone (N=191), or a third (booster) dose of COVID-19 mRNA vaccine (nucleoside modified) administered alone (N=189).
Immune responses to both vaccines were observed after co-administration of Prevenar 20 and COVID-19 mRNA vaccine (nucleoside modified). OPA GMTs for the 20 pneumococcal serotypes were similar to Prevenar 20 administered alone and IgG GMCs for the full-length S-binding protein were similar to COVID-19 mRNA vaccine (nucleoside modified) administered alone. A post-hoc analysis found the immune responses to all 20 serotypes elicited by Prevenar 20 when co-administered with COVID-19 mRNA vaccine (nucleoside modified) would have met conventional 2-fold noninferiority criteria compared to Prevenar 20 alone. Additionally, the full-length S-binding IgG GMC and reference strain neutralizing GMT elicited by COVID-19 mRNA vaccine (nucleoside modified) would have met conventional 1.5-fold noninferiority criteria compared to COVID-19 mRNA vaccine (nucleoside modified) alone.
Immune responses in special populations: Individuals with the conditions described as follows have an increased risk of pneumococcal disease.
Experience from clinical studies with Prevenar 13 (a pneumococcal conjugate vaccine consisting of 13 polysaccharide conjugates that are also in Prevenar 20) are available in adults and children with HIV infection or HSCT, and children with SCD. These data are relevant to Prevenar 20, since both vaccines are manufactured and formulated similarly and contain 13 of the same polysaccharide conjugates.
Participants who were healthy, or with stable non-immunocompromising chronic medical conditions, in all the age groups analysed had a lower immune response with Prevenar 20 compared with Prevenar 13 in spite of meeting the predefined non-inferiority margins. The clinical relevance of this observation is unknown.
Sickle cell disease: An open-label single-arm study in France, Italy, UK, US, Lebanon, Egypt and Saudi Arabia with 2 doses of Prevenar 13 given 6 months apart was conducted in 158 children and adolescents 6 to less than 18 years of age with SCD who were previously vaccinated with one or more doses of PPSV23 vaccine at least 6 months prior to enrolment. After the first vaccination, Prevenar 13 elicited antibody levels measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared to levels prior to vaccination. After the second dose immune responses were comparable to those after the first dose. One year after the second dose, antibody levels measured by both IgG GMCs and OPA GMTs were higher than levels prior to the first dose of Prevenar 13, except for the IgG GMCs for serotypes 3 and 5 that were numerically similar.
HIV infection: Adults and children not previously vaccinated with a pneumococcal vaccine: In Study 6115A1-3002 (B1851021), 151 HIV-infected participants 6 to less than 18 years of age and 152 participants greater than 18 years of age (CD4 ≥200 cells/μL, viral load <50,000 copies/mL and free of active acquired immunodeficiency syndrome [AIDS]-related illness) not previously vaccinated with a pneumococcal vaccine were enrolled to receive 3 doses of Prevenar 13. As per the general recommendations, a single dose of PPSV23 was subsequently administered. The vaccines were administered at 1-month intervals. Immune responses were assessed in 128 to 133 evaluable participants 6 to less than 18 years of age and in 131 to 137 evaluable participants greater than 18 years of age approximately 1 month after each dose of the vaccine. After the first dose, Prevenar 13 elicited antibody levels, measured by both IgG GMCs and OPA GMTs, that were statistically significantly higher compared with levels prior to vaccination. After the second and third dose of Prevenar 13, immune responses were similar to or higher than those after the first dose.
Adults previously vaccinated with PPSV23: In Study 6115A1-3017 (B1851028), immune responses were assessed in 329 HIV-infected participants 18 years of age and older (CD4+ T-cell count ≥200 cells/μL and viral load <50,000 copies/mL) previously vaccinated with PPSV23 administered at least 6 months prior to enrolment. Participants received 3 doses of Prevenar 13: at enrolment, 6 months, and 12 months after the first dose of Prevenar 13. After the first vaccination, Prevenar 13 elicited antibody levels measured by IgG GMCs and OPA GMTs that were statistically significantly higher compared with levels prior to vaccination. After the second and third dose of Prevenar 13, immune responses were comparable to or higher than those after the first dose. Participants who received previously 2 or more doses of PPSV23 showed a similar immune response compared to participants who previously received a single dose.
Hematopoietic stem cell transplant (HSCT): In Study 6115A1-3003 (B1851022), 61 participants 2 to less than 18 years of age and 190 participants 18 years of age and older with an allogeneic HSCT were enrolled to receive 3 doses of Prevenar 13 with an interval of at least 1 month between doses. The first dose was administered at 3 to 6 months after HSCT. A fourth (booster) dose of Prevenar 13 was administered 6 months after the third dose. As per the general recommendations, a single dose of PPSV23 was administered 1 month after the fourth dose of Prevenar 13. Immune responses as measured by IgG GMCs were assessed in 41 to 52 evaluable participants 2 to less than 18 years of age and in 127 to 159 evaluable participants 18 years of age and older approximately 1 month after vaccination. Prevenar 13 elicited increased antibody levels after each dose. Immune responses after the fourth dose of Prevenar 13 were significantly increased for all serotypes compared with those after the third dose with the exception of serotype 3 in the 2 to less than 18 years age group. Overall, participants 2 to less than 18 years of age had generally higher serotype-specific immune responses as compared to those 18 years of age and older.
This study demonstrated that 4 doses of Prevenar 13 elicited serum IgG concentrations similar to those induced by a single dose in healthy participants of the same age group.
Paediatric population: The safety and efficacy of Prevenar 20 in infants below 6 weeks of age have not been established. No data are available.
Pharmacokinetics: Not applicable.
Toxicology: Preclinical safety data: Non-clinical data revealed no special hazard for humans based on conventional studies of repeated-dose toxicity and reproduction and developmental toxicity.

Active immunisation for the prevention of invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in infants, children, and adolescents from 6 weeks to less than 18 years of age.
Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
See Precautions and Pharmacology: Pharmacodynamics under Actions for information on protection against specific pneumococcal serotypes.
Prevenar 20 should be used in accordance with official recommendations.

Posology: It is recommended that infants who receive a first dose of Prevenar 20 complete the vaccination course with Prevenar 20. (See Table 6.)

Click on icon to see table/diagram/image

Paediatric population: No or only limited data are available for Prevenar 20 in infants below 6 weeks, preterm, older unvaccinated, or partially vaccinated infants and children (see Precautions, Adverse Reactions and Pharmacology: Pharmacodynamics under Actions). The following dosing recommendations are predominantly based on experience with Prevenar 13.
Infants below 6 weeks of age: The safety and efficacy of Prevenar 20 in infants below 6 weeks have not been established. No data are available.
Preterm infants (less than 37 weeks of gestation): The recommended immunisation series for Prevenar 20 consists of four doses, each of 0.5 mL. The primary infant series consists of three doses, with the first dose given at 2 months of age and with an interval of at least 4 weeks between doses. The first dose may be given as early as 6 weeks of age. The fourth (booster) dose is recommended between 11 and 15 months of age (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Unvaccinated infants 7 months to less than 12 months of age: Two doses, each of 0.5 mL, with an interval of at least 4 weeks between doses. A third dose is recommended in the second year of life.
Unvaccinated children 12 months to less than 24 months of age: Two doses, each of 0.5 mL, with an interval of at least 8 weeks between doses.
Unvaccinated children 2 years to less than 5 years of age: One single dose of 0.5 mL.
Children 15 months to less than 5 years of age previously fully vaccinated with Prevenar 13: One single dose (0.5 mL) given on an individual basis according to official recommendations to elicit immune responses to the additional serotypes.
If Prevenar 13 was administered, at least 8 weeks should elapse before administering Prevenar 20 (see Pharmacology: Pharmacodynamics under Actions).
Children and adolescents 5 years to less than 18 years of age regardless of prior Prevenar 13 vaccination: One single dose (0.5 mL) given on an individual basis according to official recommendations.
If Prevenar 13 was administered, at least 8 weeks should elapse before administering Prevenar 20 (see Pharmacology: Pharmacodynamics under Actions).
Special populations: There are no data with Prevenar 20 in special populations.
Experience from clinical studies with Prevenar 13 (a pneumococcal conjugate vaccine consisting of 13 polysaccharide conjugates that are also in Prevenar 20) are available in children and adults at higher risk of pneumococcal infection including immunocompromised children and adults with human immunodeficiency virus (HIV) infection or haematopoietic stem cell transplant (HSCT), and children with sickle cell disease (SCD) (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Based on these data, the following posology was recommended for Prevenar 13: Individuals at higher risk of pneumococcal infection (e.g., individuals with SCD or HIV infection), including those previously vaccinated with 1 or more doses of PPSV23, were recommended to receive at least 1 dose of Prevenar 13.
In individuals with a HSCT, the recommended immunisation series with Prevenar 13 consisted of 4 doses of 0.5 mL each. The primary series consisted of 3 doses, with the first dose given 3 to 6 months after HSCT and with an interval of at least 4 weeks between doses. A booster dose was recommended 6 months after the third dose (see Pharmacology: Pharmacodynamics under Actions).
The recommended dosing of Prevenar 13 may be considered in guiding vaccination with Prevenar 20 in high-risk populations. For information on responses to pneumococcal vaccines in immunocompromised individuals, also refer to Precautions. and Pharmacology: Pharmacodynamics under Actions.
Method of administration: For intramuscular use only.
Prevenar 20 (0.5 mL) should be given by intramuscular injection in the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults. The vaccine should not be injected in the gluteal area. Prevenar 20 should be administered with care to avoid injection into or near nerves and blood vessels. Do not administer Prevenar 20 intravascularly.
For instructions on the handling of the vaccine before administration, see Special precautions for disposal and other handling under Cautions for Usage.

Overdose with Prevenar 20 is unlikely due to its presentation as a pre-filled syringe.

Hypersensitivity to the active substances, to any of the excipients listed in Description, or to diphtheria toxoid.

Do not inject Prevenar 20 intravascularly.
Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hypersensitivity: As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.
Concurrent illness: Vaccination should be postponed in individuals suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.
Thrombocytopenia and coagulation disorders: The vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.
The risk of bleeding in patients with coagulation disorders needs to be carefully evaluated before intramuscular administration of any vaccine, and subcutaneous administration should be considered if the potential benefit clearly outweighs the risks.
Protection against pneumococcal disease: Prevenar 20 will only protect against Streptococcus pneumoniae serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease, pneumonia or otitis media (OM). As with any vaccine, Prevenar 20 may not protect all individuals receiving the vaccine from pneumococcal invasive disease, pneumonia or OM. For most recent epidemiological information, the patient should consult with the relevant health authority.
Immunocompromised individuals: Safety and immunogenicity data on Prevenar 20 are not available for individuals in immunocompromised groups. Vaccination should be considered on an individual basis.
Based on experience with pneumococcal vaccines, some individuals with altered immunocompetence may have reduced immune responses to Prevenar 20.
Individuals with impaired immune response, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunisation. The clinical relevance of this is unknown.
Safety and immunogenicity data with Prevenar 13 (a pneumococcal conjugate vaccine consisting of 13 polysaccharide conjugates that are also in Prevenar 20) are available for individuals with HIV infection, SCD, or with HSCT (see Adverse Reactions and Pharmacology: Pharmacodynamics under Actions). Prevenar 20 should be used in accordance with official recommendations.
In adults across all studied age groups, formal non-inferiority criteria were met although numerically lower geometric mean titres were observed with Prevenar 20 for most of the serotypes compared to Prevenar 13 (see Pharmacology: Pharmacodynamics under Actions), however the clinical relevance of this observation for immunocompromised individuals is unknown.
Paediatric population: As with all injectable paediatric vaccines, the potential risk of apnoea should be considered when administering the primary immunisation series to preterm infants. The need for monitoring for at least 48 hours after vaccination should be considered for every preterm infant born ≤28 weeks of gestation who remain hospitalised at the time of the recommended administration. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.
Excipient: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
Effects on ability to drive and use machines: Prevenar 20 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under Adverse Reactions may temporarily affect the ability to drive or use machines.

Pregnancy: There are no data on the use of Prevenar 20 in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
Administration of Prevenar 20 in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
Breast-feeding: It is unknown whether Prevenar 20 is excreted in human milk.
Fertility: No human data on the effect of Prevenar 20 on fertility are available. Animal studies do not indicate direct or indirect harmful effects with respect to female fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions).

Summary of the safety profile: The safety of Prevenar 20 was evaluated in 5,987 participants 6 weeks to less than 18 years of age in four randomised, double-blind, active-controlled clinical trials and one single-arm clinical trial (one Phase 2 and four Phase 3); 3,664 participants received at least 1 dose of Prevenar 20, and 2,323 participants received Prevenar 13 (control vaccine).
Participants 6 weeks to less than 15 months of age: Clinical trials were conducted in healthy infants 6 weeks to less than 15 months of age using a 3-dose schedule or a 4-dose schedule (see Pharmacology: Pharmacodynamics under Actions). In these infant trials, 5,156 participants received at least 1 dose of vaccine: 2,833 received Prevenar 20 and 2,323 received Prevenar 13. Overall, approximately 90% of participants in each group received all doses through the study-specified toddler dose. In all studies, local reactions and systemic events were collected after each dose, and adverse events (AEs) were collected in all studies from the first dose through 1 month after the last infant vaccination and from the toddler dose through 1 month after the toddler dose. Serious adverse events were evaluated through 1 month after the last dose in the Phase 3 trial B7471012 (Study 1012) and through 6 months after the last dose in Phase 3 trials (Studies 1011, 1013) and Phase 2 trial (Study 1003).
Prevenar 20 was well tolerated when administered in a 3-dose and a 4-dose series, in the infant study populations with low rates of severe local reactions and systemic events, and most reactions resolving within 1 to 3 days. The percentages of participants with local reactions and systemic events after Prevenar 20 were generally similar to those after Prevenar 13. The most frequently reported local reactions and systemic events after any dose of Prevenar 20 were irritability, drowsiness, and pain at injection site. In these studies, Prevenar 20 was co-administered or permitted to be administered with certain routine paediatric vaccines (see Interactions).
Study 1012 was a pivotal, double-blind, randomised, active-controlled Phase 3 trial, in which 601 healthy infants received Prevenar 20 in a 3-dose series. The most frequently reported (>10%) adverse reactions after any dose of Prevenar 20 were irritability (71.0% to 71.9%), drowsiness/increased sleep (50.9% to 61.2%), pain at injection site (22.8% to 42.4%), decreased appetite (24.7% to 39.3%), redness at the injection site (25.3% to 36.9%), swelling at the injection site (21.4% to 29.8%), and fever ≥38.0°C (8.9% to 24.3%). Most adverse reactions occurred within 1 to 2 days following vaccination and were mild or moderate in severity and of short duration (1 to 2 days).
Studies 1011, 1013 and 1003, were double-blind, randomised, active-controlled trials that included 2,232 healthy infants, vaccinated with Prevenar 20 in a 4-dose series. The most frequently reported (>10%) adverse reactions observed after any dose of Prevenar 20 in infants were irritability (58.5% to 70.6%), drowsiness/increased sleep (37.7% to 66.2%), pain at injection site (32.8% to 45.5%), decreased appetite (23.0% to 26.4%), redness at the injection site (22.6% to 24.5%), and swelling at the injection site (15.1% to 17.6%). Most adverse reactions were mild or moderate following vaccination and most reactions resolving within 1 to 3 days. Severe reactions were reported infrequently.
In Study 1013, the local reactions and systemic events in the preterm subgroup (111 infants born at 34 to less than 37 weeks of gestation) were similar to or lower than the term infants in the study. In the preterm subgroup, the frequency of any reported local reaction was 31.7% to 55.3% in the Prevenar 20 group, and any systemic event was 65.0% to 85.5% in the Prevenar 20 group.
Participants 15 months to less than 18 years of age: In the Phase 3 trial B7471014 (Study 1014), 831 participants 15 months to less than 18 years of age received a single dose of Prevenar 20 in four age groups (209 participants 15 to less than 24 months of age; 216 participants 2 years to less than 5 years of age; 201 participants 5 years to less than 10 years age; and 205 participants 10 years to less than 18 years of age). The participants less than 5 years of age had received at least 3 prior doses of Prevenar 13.
The most frequently reported adverse reactions (>10%) observed after any dose of Prevenar 20 in participants less than 2 years of age were irritability (61.8%), pain at the injection site (52.5%), drowsiness/increased sleep (41.7%), redness at the injection site (37.7%), decreased appetite (25.0%), swelling at the injection site (22.1%) and fever ≥38.0°C (11.8%). In participants aged 2 years and older, the most frequently reported adverse reactions were pain at the injection site (66.0% to 82.9%), muscle pain (26.5% to 48.3%), redness at the injection site (15.1% to 39.1%), fatigue (27.8% to 37.2%), headache (5.6% to 29.3%), and swelling at the injection site (15.6% to 27.1%).
Participants 18 years of age and older: The safety of Prevenar 20 was evaluated in 4,552 participants 18 years of age and older in six clinical trials (two Phase 1, one Phase 2, and three Phase 3), and 2,496 participants in the control groups.
In the Phase 3 trials, 4,263 participants received Prevenar 20. This, included 1,798 participants 18 through 49 years of age, 334 participants 50 through 59 years of age, and 2,131 participants 60 years of age and older (1,138 were 65 years of age and older). Of the participants who received Prevenar 20 in the Phase 3 trials, 3,639 were naïve to pneumococcal vaccines, 253 had previously received Pneumovax 23 (pneumococcal polysaccharide vaccine [23-valent]; PPSV23) (≥1 to ≤5 years prior to enrolment), 246 had previously received Prevenar 13 only (≥6 months prior to enrolment), and 125 had previously received Prevenar 13 followed by PPSV23 (the dose of PPSV23 ≥1-year prior to enrolment).
Participants in the Phase 3 trial B7471007 (Pivotal Study 1007) were evaluated for adverse events for 1 month after vaccination, and serious adverse events through 6 months after vaccination. This study included 447 participants 18 to 49 years of age, 445 participants 50 to 59 years of age, 1,985 participants 60 to 64 years of age, 624 participants 65 to 69 years of age, 319 participants 70 to 79 years of age, and 69 participants ≥80 years of age.
In participants 18 to 49 years of age in Studies 1007 and a Phase 3 trial B7471008 (Lot Consistency Study 1008), the most frequently reported adverse reactions were pain at injection site (79.2%), muscle pain (62.9%), fatigue (46.7%), headache (36.7%), and joint pain (16.2%). In participants 50 to 59 years of age in Study 1007, the most frequently reported adverse reactions were pain at injection site (72.5%), muscle pain (49.8%), fatigue (39.3%), headache (32.3%), and joint pain (15.4%). In participants ≥60 years of age in Study 1007, the most frequently reported adverse reactions were pain at injection site (55.4%), muscle pain (39.1%), fatigue (30.2%), headache (21.5%), and joint pain (12.6%). These were usually mild or moderate in intensity and resolved within a few days after vaccination.
Phase 3 Study B7471006 (Study 1006) evaluated Prevenar 20 in participants ≥65 years of age with varying prior pneumococcal status (prior PPSV23, prior Prevenar 13 or prior Prevenar 13 followed by PPSV23). In this study, the most frequently reported adverse reactions for participants were similar in frequency to those described for participants ≥60 years of age in Study 1007, with slightly higher injection site pain (61.2%) in participants with prior Prevenar 13, and joint pain (16.8%) in participants with prior Prevenar 13 followed by PPSV23.
Tabulated list of adverse reactions: Tabulated lists of adverse reactions from the Phase 2 infant trial, and Phase 3 clinical trials in paediatric and adult populations, and postmarketing experience are presented as follows.
Adverse reactions from clinical trials: As Prevenar 20 contains the same 13 serotype-specific capsular polysaccharide conjugates and the same vaccine excipients as Prevenar 13, the adverse reactions already identified for Prevenar 13 have been adopted for Prevenar 20. Table 7 presents adverse reactions reported in the Phase 2 infant trial, and Phase 3 trials in paediatric and adult populations, based on the highest frequency among adverse reactions, local reactions, or systemic events, after vaccination in a Prevenar 20 group in a study or integrated dataset. The data from clinical trials in infants reflect Prevenar 20 administered simultaneously with other routine childhood vaccines. In the case of adverse reactions reported in clinical trials of Prevenar 13, but not reported in Prevenar 20 trials, the frequency is not known. In clinical trials, the safety profile of Prevenar 20 was similar to that of Prevenar 13. No new adverse reactions were identified as compared to Prevenar 13.
Adverse reactions are listed by system organ class in decreasing order of frequency and seriousness. The frequency is defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from available data). (See Table 7.)

Click on icon to see table/diagram/image

Safety with concomitant vaccine administration: Adults: The safety profile was similar when Prevenar 20 was administered with or without influenza vaccine, adjuvanted (Fluad Quadrivalent [QIV]).
Prevenar 20 administered together with COVID-19 mRNA vaccine (nucleoside modified) was observed to have a tolerability profile similar to COVID-19 mRNA vaccine (nucleoside modified) administered alone, and an overall safety profile consistent with Prevenar 20 or COVID-19 mRNA vaccine (nucleoside modified) given alone.
Adverse reactions from postmarketing experience: Table 8 includes adverse experiences that have been spontaneously reported during the postmarketing use of Prevenar 13 in paediatric and adult populations, which may also occur with Prevenar 20. The postmarketing safety experience with Prevenar 13 is relevant to Prevenar 20, as Prevenar 20 contains all components (polysaccharide conjugates and excipients) of Prevenar 13. These events were reported voluntarily from a population of uncertain size. Therefore, it is not possible to reliably estimate their frequency or to establish, for all events, a causal relationship to vaccine exposure. (See Table 8.)

Click on icon to see table/diagram/image

Additional information in special populations in studies with Prevenar 13: Participants 6 to <18 years of age with HIV infection have similar frequencies of adverse reactions in Table 7, except fever (11% to 19%), joint pain (24% to 42%), and vomiting (8% to 18%), which were very common. Participants ≥18 years of age with HIV infection have similar frequencies of adverse reactions in Table 7, except for pyrexia (5% to 18%) and vomiting (8% to 12%) which were very common and nausea (<1% to 3%) which was common.
Participants 2 to <18 years of age with HSCT have similar frequencies of adverse reactions in Table 7, except vaccination-site pain causing limitation of limb movement (5% to 15%), vomiting (6% to 21%), diarrhoea (15% to 32%), and joint pain (25% to 32%), which were very common. Participants ≥18 years of age with an HSCT have similar frequencies of adverse reactions in Table 7, except for pyrexia (4% to 15%), vomiting (6% to 21%), and diarrhoea (25% to 36%) which were very common.
Participants 6 to <18 years of age with SCD have similar frequencies of adverse reactions in Table 7, except vaccination-site pain causing limitation of limb movement (11% to 16%), fever (21% to 22%), vomiting (13% to 15%), diarrhoea (13% to 25%), and joint pain (40% to 45%), which were very common.

Different injectable vaccines should always be given at different vaccination sites.
Do not mix Prevenar 20 with other vaccines/medicinal products in the same syringe.
Paediatric population: In infants and children, 6 weeks to less than 5 years of age, Prevenar 20 can be administered concomitantly with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular pertussis, hepatitis B, Haemophilus influenzae type b, inactivated poliomyelitis, measles, mumps, rubella, and varicella vaccines. In clinical trials, rotavirus vaccines were permitted to be administered concomitantly with Prevenar 20 and no safety concerns were observed.
Individuals 18 years of age and older: Prevenar 20 can be administered concomitantly with influenza vaccine, adjuvanted (Fluad Quadrivalent [QIV]) and COVID 19 mRNA vaccine (nucleoside modified) (see Pharmacology: Pharmacodynamics under Actions).
No data are currently available regarding concomitant use with other vaccines.

Incompatibilities: In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.
Special precautions for disposal and other handling: During storage, a white deposit and clear supernatant may be observed in the pre-filled syringe containing the suspension. Pre-filled syringes should be stored horizontally to minimise the resuspension time.
Preparation for administration: Step 1. Vaccine resuspension: Hold the pre-filled syringe horizontally between the thumb and the forefinger and shake vigorously until the contents of the syringe are a homogeneous white suspension. Do not use the vaccine if it cannot be resuspended.
Step 2. Visual inspection: Visually inspect the vaccine for large particulate matter and discolouration prior to administration. Do not use if large particulate matter or discolouration is found. If the vaccine is not a homogenous white suspension, repeat steps 1 and 2 as previously mentioned.
Step 3. Remove syringe cap: Remove the syringe cap from the Luer lock adapter by slowly turning the cap counter-clockwise while holding the Luer lock adapter.
Note: Care should be taken to ensure that the extended plunger rod is not depressed while removing the syringe cap.
Step 4. Attach a sterile needle: Attach a needle appropriate for intramuscular administration to the pre-filled syringe by holding the Luer lock adapter and turning the needle clockwise.
Any unused product or waste material should be disposed of in accordance with local requirements.

Store in a refrigerator (2°C to 8°C). Pre-filled syringes should be stored in the refrigerator horizontally to minimise the resuspension time.
Do not freeze. Discard if the vaccine has been frozen.
From a microbiological point of view, once removed from the refrigerator, the vaccine should be used immediately.
Stability data indicate that the vaccine is stable for 96 hours when stored at temperatures from 8°C to 25°C, or 72 hours when stored at temperatures from 0°C to 2°C. At the end of these time periods Prevenar 20 should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.

Vaccines, Antisera & Immunologicals

J07AL02 - pneumococcus, purified polysaccharides antigen conjugated ; Belongs to the class of pneumococcal bacterial vaccines.

POM